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Background: Rac3 is a small GTPase multifunctional protein that regulates cell adhesion, migration, and
differentiation. It has been considered as an oncogene in breast cancer; however, its role in esophageal cancer and
the regulation of its stability have not been studied. F-box proteins are major subunits within the Skp1-Cullin-1-F-
box (SCF) E3 ubiquitin ligases that recognize particular substrates for ubiquitination and proteasomal degradation.
Recently, we have shown that SCFFBXL19 targets Rac1 and RhoA, thus regulating Rac1 and RhoA ubiquitination and
degradation. Here, we demonstrate the role of FBXL19 in the regulation of Rac3 site-specific ubiquitination and
stability. Expression of TGFβ1 is associated with poor prognosis of esophageal cancer. TGFβ1 reduces tumor
suppressor, E-cadherin, expression in various epithelial-derived cancers. Here we investigate the role of FBXL19-
mediated Rac3 degradation in TGFβ1-induced E-cadherin down-regulation in esophageal cancer cells.
Methods: FBXL19-regulated endogenous and over-expressed Rac3 stability were determined by immunoblotting
and co-immunoprecipitation. Esophageal cancer cells (OE19 and OE33) were used to investigate TGFβ1-induced
E-cadherin down-regulation by Immunoblotting and Immunostaining.
Results: Overexpression of FBXL19 decreased endogenous and over-expressed Rac3 expression by interacting and
polyubiquitinating Rac3, while down-regulation of FBXL19 suppressed Rac3 degradation. Lysine166 within Rac3 was
identified as an ubiquitination acceptor site. The FBXL19 variant with truncation at the N-terminus resulted in an
increase in Rac3 degradation; however, the FBXL19 variant with truncation at the C-terminus lost its ability to
interact with Rac3 and ubiquitinate Rac3 protein. Further, we found that Rac3 plays a critical role in TGFβ1-induced
E-cadherin down-regulation in esophageal cancer cells. Over-expression of FBXL19 attenuated TGFβ1-induced
E-cadherin down-regulation and esophageal cancer cells elongation phenotype.
Conclusions: Collectively these data unveil that FBXL19 functions as an antagonist of Rac3 by regulating its stability
and regulates the TGFβ1-induced E-cadherin down-regulation. This study will provide a new potential therapeutic
strategy to regulate TGFβ1 signaling, thus suppressing esophageal tumorigenesis.
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Rac3 (ras-related C3 botulinum toxin substrate 3) is a
member of the RhoGTPase family. In its active form, it
is bound to GTP, whereas it is inactive in its GDP-
bound form. It has been well studied that activation of
RhoGTPases is controlled by guanidine activating pro-
teins (GEFs) that exchange bound GDP to GTP and by
GTPase activating proteins (GAPs) that promote GTP
hydrolysis. Rac3 is enriched in the brains but it also
expressed in a wide range of tissues [1]. Aberrant activa-
tion of Rac3 has been recognized to be important in
tumor proliferation in both breast cancer and prostate
cancer [2,3]. Rac3 regulates a variety of cellular functions
including adhesion, cell migration, and differentiation.
The controversial effects of Rac3 on cell migration have
been reported. Rac3 negatively regulates diapedesis of
prostate cancer cell PC3, since knockdown of Rac3 using
Rac3 specific siRNA increased migration of PC3 cells
through a bone marrow endothelial cell layer [4]. In con-
trast, overexpression of Rac3 promotes estrogen-induced
breast cancer cell migration [2]. Rac3 was found to be
involved in breast cancer cell aggressiveness through the
activation of NF-κB and Erk2. Inhibition of Rac3 caused
an increase in TNFα-induced apoptosis [5]. However,
the role of Rac3 in the pathogeneses of esophageal can-
cer has not been studied.
Many posttranslational modifications, including ubi-
quitination, expand the size of the proteome exponen-
tially and are pivotal in the regulation of protein stability
[6-9]. The ubiquitin proteasome system (UPS) regulates
protein ubiquitination, and therefore degradation and
turnover, of many proteins vital of cellular regulation
and function [10]. The UPS depends upon the action of
three enzyme complexes. The E1 enzyme functions as
an activator by creating a thioester bond between a cyst-
eine of the E1 enzyme and the ubiquitin molecule via
ATP hydrolysis. E2, known as the conjugating enzyme,
then accepts the ubiquitin protein onto an active site
cysteine. Finally, the E3 ligating enzyme complex is re-
sponsible for attachment of this ubiquitin protein to a
lysine of the target protein [11]. Among the families of
E3 ubiquitin ligases, the Skp1-Cullin-1-F-box protein
(SCF) ligases complex is one of the largest. In this com-
plex, the F-box protein is the substrate-recognition com-
ponent [12,13]. F-box proteins have two main domains:
an F-box motif and a substrate binding motif. F-box pro-
teins use their F-box motif to bind to Skp1 and assemble
the SCF ligase complex, whereas the substrate-binding
motif is used for recognition and interaction with phos-
phorylated substrates [14]. Through an in silico search,
the ‘orphan’ F-box protein FBXL19 has been identified
and verified as an SCF E3 subunit [15]. Recently, we
demonstrated that FBXL19 regulates interleukin (IL)-33
signaling by targeting its cognate receptor ST2L, forubiquitination, which, in turn, triggers its proteasomal
degradation to alter the innate immune response [16]. In
addition to ST2L, we also found that Rac1 and RhoA are
targets for FBXL19 and revealed new functions of
FBXL19 in regulating cell migration, proliferation and
cytoskeleton rearrangement [17,18].
E-cadherin, a type I classical cadherin, is a key compo-
nent in the formation of cell-cell adherens-type junc-
tions in epithelial tissues [19-21]. A variety of studies in
cancers, including hepatocellular carcinoma, squamous
cell carcinomas of the skin, head and neck, and pancre-
atic cancer, have demonstrated that E-cadherin plays a
critical role as a tumor suppressor [22-25]. E-cadherin is
often down-regulated during carcinoma progression and
metastatic spread of tumors [26,27]. Loss of E-cadherin
changes cancer cell phenotype and facilitates the initial
invasive behaviors of epithelial-derived cancer [28].
Transforming growth factor β (TGFβ), a pleiotropic
cytokine comprised of three isoforms in mammalian
cells, function as a tumor promoting mediator in the
later stages of cancers [29,30]. TGFβ1 signaling has been
shown to play an important role in down-regulation of
E-cadherin. It appears, that many epithelial tumors es-
cape growth inhibition by TGFβ1, and TGFβ1 secretion
by cancer may contribute to late tumor progression
[31,32]. It has been shown that TGFβ1 expression is
higher in esophageal cancer tissues, compared to normal
squamous epithelium and non-malignant Barrett’s mu-
cosa [33]. Over-expression of TGFβ1 in esophageal can-
cer is associated with advanced stage of disease and poor
prognosis [34].
In this study, we demonstrate that Rac3 is a target
protein of SCFFBXL19 E3 ligase. FBXL19 regulates Rac3
stability by ubiquitinating Rac3 on lysine 166 residue.
This is the first report to reveal that Rac3 is implicated
in TGFβ1-induced E-cadherin down-regulation in
esophageal cancer cells. Further, we found that over-
expression of FBXL19 attenuates the effect of TGFβ1 on
E-cadherin down-regulation. This study will provide a
molecular basis for SCF E3 ligase in the regulation of
esophageal tumorigenesis.
Results
FBXL19 reduces Rac3 protein expression
We have demonstrated that SCFFBXL19 ligase targeted
Rac1 and RhoA for its ubiquitination and degradation
[17,18]. To investigate if the FBXL19 also regulates
Rac3 degradation, we transfected with V5-tagged FBX
L19 (FBXL19-V5) and hemagglutinin-tagged FBXL19
(FBXL19-HA) plasmids in HEK293 cells respectively. Both
forms of tagged-FBXL19 down-regulated endogenous
Rac3 expression (up to ~73%) (Figure 1A-B), while over-
expression of other E3 ligase subunits (NEDD4L, FBXL18,
and FBXL22) had no effect on Rac3 expression
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Figure 1 FBXL19 induces Rac3 degradation - A. HEK293 cells were transfected with V5 or HA tagged FBXL19 (FBXL19-V5 or FBXL19-HA)
plasmid for 48 h. Cells lysates were analyzed by immunoblotting with Rac3, V5 tag, HA tag, and β-actin antibodies. B. Rac3 levels in Figure 1A
were quantified by Image J software. C. HEK293 cells were transfected with V5 tagged Nedd4L, FBXL18, or FBXL22 plasmid for 48 h. Cell lysates
were analyzed by immunoblotting with Rac3, V5 tag, and β-actin antibodies. D. Cell lysates from MLE12, HEK293, A549, and OE19 were analyzed by
immunoblotting with Rac3, Rac1, and β-actin antibodies. E. MLE12 cells were co-transfected with V5 tagged Rac3 (Rac3-V5) and FBXL19-V5 (0–2 μg)
plasmids for 48 h and then the cell lysates were analyzed by immunoblotting with V5 tag and β-actin antibodies. F. MLE12 cells were co-transfected with
Rac3-V5 and FBXL19-HA (0–4 μg) plasmids for 48 h and then the cell lysates were analyzed by immunoblotting with V5 tag, HA tag and β-actin
antibodies. G. MLE12 cells were co-transfected with Rac3-V5, Cont shRNA, or one of the three FBXL19shRNAs (#1, #2, and #3) plasmids for 48 h and then
the cell lysates were analyzed by immunoblotting with V5 tag, FBXL19 and β-actin antibodies. Rac3-V5 levels were quantified by Image J software.
H. Total RNA was extracted from empty vector- or FBXL19-V5 plasmid-transfected HEK293 cells, Rac3 mRNA levels were then examined by RT-real time
PCR with specifically designed Rac3 primers. All the blots are representative of three independent experiments.
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body, we examined the Rac3 and Rac1 expression in sev-
eral cell lines including MLE12, HEK293, A549, and OE19
cells. As shown in Figure 1D, Rac3 was highly expressed
in HEK293 and OE19 cells compared to its expression in
A549 cells. It was not detectable in MLE12 cells. Rac1 was
highly expressed all the cell lines, suggesting Rac3 anti-
body does not cross-react with Rac1 protein. Further, we
examined if FBXL19 reduces over-expressed Rac3 levels.
Since Rac3 is not detectable in MLE12 cells (Figure 1D),
we used MLE12 cells for studying the stability of over-
expressed Rac3. We co-overexpressed V5-tagged Rac3(Rac3-V5) with different doses of FBXL19-V5 or FBXL19-
HA plasmid in MLE12 cells. Figure 1E and F show that
the ectopic expression of FBXL19-V5 or FBXL19-HA di-
minished Rac3-V5 protein in a dose dependent manner.
Further, we examined the effect of FBXL19 down-
regulation on Rac3-V5 expression. MLE12 cells were
transfected with Rac3-V5 and three individual FBXL19
shRNAs. As shown in Figure 1G, FBXL19 shRNAs (#2
and #3 only) reduced FBXL19 expression (up to ~50-
70%), while Rac3-V5 protein mass was dramatically en-
hanced around 2.5 fold. To examine if the effect of
FBXL19 on the reduction of Rac3 protein mass is due to
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Rac3 mRNA levels by RT-realtime PCR. FBXL19-V5 had
no effect on Rac3 mRNA expression, suggesting that
FBXL19-mediated Rac3 reduction is through the regula-
tion of Rac3 protein stability.
FBXL19 induces Rac3 degradation in the proteasome
system
In the process of investigating the degradation of the Rac3
protein, we examined if Rac3 degradation is mediated in
the ubiquitin-proteasome system. We found that adminis-
tration of FBS-free (blank) medium diminished Rac3-V5
in a time-dependent manner (Figure 2A). To identify
which pathway is involved in the degradation of Rac3,
Rac3-V5 overexpressed cells were treated with inhibitors
of proteasomes (MG-132) or lysosomes (leupeptin) prior
to administration of blank medium. Starvation-mediatedA
B
Figure 2 FBXL19 induces Rac3 degradation in the proteasome system
were treated with MG-132 (20 μM) or leupeptin (100 μM) treatment for 1 h
lysates were analyzed by immunoblotting with V5 tag and β-actin antibod
were transfected with FBXL19-V5 plasmid for 48 h, and then the cells were
or NH4Cl (20 mM) for 4 h. Cells lysates were analyzed by immunoblotting
by Image J software. C. MLE12 cells were co-transfected with Rac3-V5 and
medium (0–4 h). Cells lysates were analyzed by immunoblotting with V5 ta
Image J software. All the blots are representative of three independent expRac3 degradation was attenuated by pretreatment
with MG-132 (up to ~67% at 4 h), but not leupeptin
(Figure 2A), suggesting Rac3 degradation is mediated in
the proteasome system, but not in the lysosome system.
In addition, we found that the FBXL19-V5-induced Rac3
degradation was attenuated by MG-132 (up to 45-53%),
but not by leupeptin (Figure 2B). The results were con-
firmed by treating cells with other inhibitors of the prote-
asome (Lactacystin) or lysosome (NH4Cl) (Figure 2B). To
further investigate the role of FBXL19 in the regulation of
Rac3 degradation, we down-regulated FBXL19 by FBXL19
shRNA transfection prior to treatment with blank
medium. Figure 2C shows that FBXL19 shRNA transfec-
tion attenuated blank medium-mediated Rac3-V5 degrad-
ation (up to ~64% at 4 h), as well as FBXL19 expression
(Figure 2C). The results suggest that FBXL19-mediated
Rac3 degradation is in the proteasome system.C
- A. MLE12 cells were transfected with Rac3-V5 plasmid for 48 h. Cells
prior to change to blank medium for indicated incubation time. Cells
ies. Rac3-V5 levels were quantified by Image J software. B. HEK293 cells
treated with MG-132 (20 μM), Lactacystin (10 μM), leupeptin (100 μM),
with Rac3, V5 tag and β-actin antibodies. Rac3 levels were quantified
shFBXL19 plasmids for 48 h, and then the cells were cultured in blank
g, FBXL19, and β-actin antibodies. Rac3-V5 levels were quantified by
eriments.
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To investigate if FBXL19 is associated with Rac3, we
overexpressed V5-tagged FBXL19 and Flag-tagged Rac3
in HEK293 cells. Immunoprecipitation (IP) with an anti-
body to the Flag tag followed by Western blotting with
an antibody to the V5 tag revealed that FBXL19-V5 asso-
ciates with Rac3-Flag (Figure 3A). Further, endogenous
Rac3 was detected in the FBXL19-V5 immunoprecipita-
tion complex (Figure 3B). To examine if FBXL19
induces Rac3 ubiquitination, cells were transfected with
Rac3-V5 and FBXL19-HA plasmids. Co-IP with an
antibody to ubiquitin followed by Western blotting with
V5 tag immunoblotting demonstrated that over-
expression of FBXL19 increased polyubiquitination of
Rac3 (Figure 3C). Lysine (K) residues within a target
protein are ubiquitin acceptor sites for linking mono- or
polyubiquitin [35]. To identify the putative ubiquitin
acceptor site within Rac3 for FBXL19, we substituted
several candidate K residues of Rac3 with arginine (R).
Of several mutants tested, only Rac3K166R-V5, not
Rac3K183R-V5 or Rac3K184R-V5, was resistant to FBXL19-
mediated degradation (Figure 4A). Further, we compared
the degree of ubiquitination of Rac3 wild type and
Rac3K166R-V5 after incubation with MG-132. As shown
in Figure 4B, polyubiquitinated Rac3 was immunopreci-
pitated by an antibody to ubiquitin, and Rac3 K166R ex-
hibits less ubiquitination, compared to Rac3 wild type,Figure 3 FBXL19 targets Rac3 for ubiquitination - A. HEK293 cells were
plasmids. Cell lysates were subjected to immunoprecipitation with a Flag ta
analyzed by immunoblotting with V5 tag and Flag tag antibodies. B. HEK29
(20 μM) treatment. Cell lysates were subjected to immunoprecipitation with
were analyzed by immunoblotting with Rac3 and β-actin antibodies. C. MLE
Cell lysates were subjected to immunoprecipitation with an ubiquitin antibo
by immunoblotting with HA tag, V5 tag and β-actin antibodies. All the blotssuggesting that K166 is an ubiquitin acceptor site within
Rac3.
Role of N-terminus and C-terminus of FBXL19 in Rac3
degradation
Next we examined which part of FBXL19 is important in
Rac3 degradation. Transfection of a plasmid encoding an
FBXL19 variant with truncation at the NH2 (N111 or
N121) resulted in increases in Rac3 degradation, com-
pared to the wild type FBXL19-V5 (Figure 5A). This in-
dicates that there is an inhibitory domain within the
N-terminus of FBXL19. Further, an FBXL19 variant with
truncation at the COOH (C450) lost the ability to degrade
Rac3 (Figure 5B). In addition, co-IP with an antibody to
the V5 tag revealed that wide type FBXL19-V5, but not
the variant with truncation at the COOH (C450), associ-
ates with Rac3-Flag in HEK293 cells (Figure 5C). It sug-
gests that Rac3 interacts with FBXL19 in the C-terminus
of FBXL19.
Rac3 regulates TGFβ1-induced E-cadherin
down-regulation
TGFβ1 is associated with poor prognosis of esophageal
cancer [34]. TGFβ1-mediated down-regulation of E-
cadherin contributes to tumor invasion and proliferation
[31]. Here, we show that TGFβ1 treatment (4 days) in-
duces E-cadherin down-regulation in a dose dependentco-transfected with Flag tagged Rac3 (Rac3-Flag) and FBXL19-V5
g antibody, followed by V5 tag immunoblotting. Input lysates were
3 cells were transfected with FBXL19-V5 plasmid followed by MG-132
a V5 tag antibody, followed by Rac3 immunoblotting. Input lysates
12 cells were co-transfected with Rac3-V5 and FBXL19-HA plasmids.
dy, followed by V5 tag immunoblotting. Input lysates were analyzed
are representative of three independent experiments.
A B
Figure 4 Lysine 166 within Rac3 is an ubiquitin acceptor site for FBXL19 - A. MLE12 cells were co-transfected with FBXL19-V5 wild type and
Rac3 lysine mutant plasmids as indicated. Cell lysates were analyzed by immunoblotting with antibodies to V5 tag and β-actin. Rac3-V5 levels were
quantified by Image J software. B. MLE12 cells were transfected with Wt Rac3-V5 or Rac3K166R-V5 plasmid. Cell lysates were subjected to
immunoprecipitation with an ubiquitin antibody, followed by V5 tag immunoblotting. Input lysates were analyzed by immunoblotting with V5 tag
and β-actin antibodies. All the blots are representative of three independent experiments.
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Further, we found that TGFβ1 reduced E-cadherin ex-
pression in another esophageal cancer cell line OE33 (up
to ~69%) (Figure 6A). To investigate if TGFβ1-mediated
E-cadherin down-regulation is associated with Rac3,
we overexpressed Rac3 inactive form (Rac3N17-V5)
(Figure 6B) or down-regulation of Rac3 by transfection
with Rac3 shRNA (Figure 6C) to inhibit Rac3 activity
prior to TGFβ1 treatment (0, 2.5, 5.0 ng/ml, 4 days) in
OE19 cells. Both the Rac3 inactive form and Rac3
shRNA attenuated the TGFβ1-reduced E-cadherin level
(up to ~34-37%) (Figure 6B and C). Snail, a transcrip-
tional factor, is well known to down-regulate E-cadherin.
Here, we found that over-expression of Rac3-V5A B
Figure 5 Role of N-terminus and C-terminus of FBXL19 in Rac3 degrada
FBXL19-V5 (Wt) or an FBXL19 variant with truncation at the NH2 (N111 or N12
β-actin antibodies. B. HEK293 cells were transfected with plasmid encoding w
(C450). Cell lysates were analyzed by immunoblotting with Rac3, V5 tag and β
FBXL19-V5 wild-type (Wt) or V5 tagged FBXL19 variant with truncation at the C
with a Flag tag antibody or IgG, followed by V5 tag immunoblotting. Input ly
antibodies. All the blots are representative of three independent experimentsincreased Snail expression by ~1.95 fold in OE19 cells
(Figure 6D). Immunostaining showed that TGFβ1 treat-
ment induced OE19 cell elongation phenotype was
attenuated by over-expression of Rac3N17 (Figure 6E
and F). These results suggest that Rac3 is involved in
TGFβ1-induced E-cadherin down-regulation.
FBXL19 regulates TGFβ1-induced E-cadherin
down-regulation
We have shown that FBXL19 mediates Rac3 degradation
and Rac3 is involved in E-cadherin down-regulation by
TGFβ1. Further, we examined if FBXL19 regulates
TGFβ1-induced E-cadherin down-regulation. First, we
confirmed the effect of FBXL19 in Rac3 degradation inC
tion - A. HEK293 cells were transfected with plasmid encoding wild-type
1). Cell lysates were analyzed by immunoblotting with Rac3, V5 tag, and
ild-type FBXL19-V5 (Wt) or an FBXL19 variant with truncation at the COOH
-actin antibodies. C. HEK293 cells were co-transfected with Rac3-Flag and
OOH (C450) plasmids. Cell lysates were subjected to immunoprecipitation
sates were analyzed by immunoblotting with V5 tag, Flag tag and β-actin
.
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Figure 6 Rac3 regulates TGFβ1-induced E-cadherin downregulation - A. OE19 cells were treated with TGFβ1 (0–10.0 ng/ml) for 4 days or OE33
cells were treated with TGFβ1 (5 ng/ml) for 4 days, and then the cell lysates were analyzed by immunoblotting with E-cadherin and β-actin antibodies.
E-cadherin levels were quantified by Image J software. B. OE19 cells were transfected with V5 tagged Rac3 inactive form (Rac3N17-V5) plasmid for 24 h
followed by treatment of TGF-β1 (0–5 ng/ml) for 4 days. The cell lysates were analyzed by immunoblotting with E-cadherin, V5 tag, and β-actin
antibodies. E-cadherin levels were quantified by Image J software. C. OE19 cells were transfected with Cont shRNA or Rac3 shRNA plasmid for 48 h
followed by the treatment with TGF-β1 (0–5 ng/ml) for 4 days. The cell lysates were analyzed by immunoblotting with E-cadherin, Rac3, and β-actin
antibodies. E-cadherin levels were quantified by Image J software. D. OE19 cells were transfected with Rac3-V5 plasmid for 48 h and then cell lysates
were analyzed by immunoblotting with Snail, V5 tag, and β-actin antibodies. Snail levels were quantified by Image J software. E. OE19 cells were
transfected with Rac3N17-V5 or vector plasmid for 24 h and then incubated with TGFβ1 (5 ng/ml) for 4 days. Cells were fixed and immunostained with
E-cadherin (green). Nuclei were stained with DAPI (red). F. Cell length was measured by Image J software. All the blots and images are representative
of three independent experiments.
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Figure 7A, FBXL19-V5 diminished Rac3 protein in a
dose dependent manner in OE19, as well as in OE33
cells. As expected, we found that FBXL19-V5 reduced
Rac3 activity in both OE19 and HEK293 cells (up to 64-
89%) (Figure 7B). Next, we overexpressed FBXL19-V5 in
OE19 and OE33 cells for 24 h prior to TGFβ1 treatment
(0, 2.5, 5.0 ng/ml, 4 days). Figure 7C shows that
FBXL19-V5 attenuated the TGFβ1-induced decrease of
E-cadherin (up to ~36% with TGFβ1 5 ng/ml treatment).
These results were also observed in OE33 cells (up to
~62%) (Figure 7D). Further, we examined the effect of
FBXL19-V5 on Rac3-mediated Snail expression. As
shown in Figure 7E, FBXL19 blocked Rac3-V5 inducedSnail expression (up to ~92% reduction) in OE19 cells.
In addition, immunostaining showed that TGFβ1 treat-
ment induced OE19 cell elongation phenotype was at-
tenuated by over-expression of FBXL19 (Figure 7F and
G) in OE19 cells. These results indicate that FBXL19 at-
tenuates the effects of TGFβ1 on E-cadherin down-
regulation and cell elongation phenotype by mediating
Rac3 degradation.
Discussion
Rho family GTPases are important intracellular signal-
ing proteins that control diverse cellular functions,
including actin cytoskeletal organization, migration and
invasion, transcriptional regulation, cell cycle progression,
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Figure 7 FBXL19 regulates TGFβ1-induced E-cadherin down-regulation - A. OE19 cells were transfected with FBXL19-V5 plasmid (0–4 μg) or
OE33 cells were transfected with FBXL19-V5 (4 μg) for 2 days, and then the cell lysates were analyzed by immunoblotting with Rac3, V5 tag and
β-actin antibodies. Rac3 levels were quantified by Image J software. B. Cell lysates from FBXL19-V5-overexpressed HEK293 or OE19 cells were
analyzed for Rac3 activity by using a PBD-GTPγ-Rac3 pull down assay. Total cell lysates were analyzed by immunoblotting with Rac3, V5, and β-actin
antibodies. Activated Rac3 levels were quantified by Image J software. C. OE19 cells were transfected with FBXL19-V5 plasmid for 24 h followed by
treatment of TGFβ1 (0–5 ng/ml) for 4 days. The cell lysates were analyzed by immunoblotting with E-cadherin, V5 tag, and β-actin antibodies.
E-cadherin levels were quantified by Image J software. D. OE33 cells were transfected with FBXL19-V5 plasmid for 24 h followed by treatment of TGFβ1
(5 ng/ml) for 4 days. The cell lysates were analyzed by immunoblotting with E-cadherin, V5 tag, and β-actin antibodies. E-cadherin levels were
quantified by Image J software. E. OE19 cells were transfected with Rac3-V5, FBXL19-V5, or Rac3-V5 + FBXL19-V5 plasmids for 48 h. Cell lysates were
then analyzed by immunoblotting with Snail, V5 tag, and β-actin antibodies. Snail levels were quantified by Image J software. F. OE19 cells were
transfected with FBXL19-V5 or vector plasmid for 24 h and then incubated with TGFβ1 (5 ng/ml) for 4 days. Cells were fixed and immunostained with
E-cadherin (green). Nuclei were stained with DAPI (red). G. Cell length was measured by Image J software. All the blots and images are representative
of three independent experiments.
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extracellular matrix adhesions [36,37]. Of the Rho family
GTPases, Rac3 is implicated in regulating cell adhesion,
growth, differentiation, and autophagy [38]. To date, little
is known regarding the molecular regulation of Rac3 sta-
bility. Here, we show that Rac3 lifespan is regulated by the
SCFFBXL19 E3 ligase and the proteasome system. FBXL19
targets Rac3 for ubiquitination in a specific lysine site,thus resulting in its degradation. Rac3, as an oncogene
protein, plays a pivotal role in tumorgenesis of a variety
type of cancers, including breast cancer and prostate can-
cer. This study is the first to report that Rac3 regulates
TGFβ1-mediated E-cadherin down-regulation in esopha-
geal cancer cells, indicating a critical role of Rac3 in the
progress of esophageal cancer. Further, we demonstrate
that FBXL19 negatively regulates Rac3-mediated TGFβ1
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http://www.molecular-cancer.com/content/13/1/76signaling in esophageal cancer. Here, we provide new evi-
dence that ubiquitin E3 ligase contributes to the tumor-
genesis of esophageal cancer. Targeting the ubiquitin E3
ligase will build a basis to develop a new potential thera-
peutic strategy to inhibit tumor growth and invasion. Des-
pite the high homology in amino-acid sequence between
Rac1 and Rac3, Rac3 differs from Rac1 in the COOH ter-
minal region, which is involved in Rac localization and
regulatory protein binding [1]. However, most of literature
addressing the role of Rac in cancer progression concern
Rac1, with little mention of Rac3. The elucidation of
mechanisms for control of Rac3 protein stability therefore
might have important implications for metastasis.
Post-translational modifications, including ubiquitina-
tion, regulate the function of key signaling proteins by
modulating their activity, localization, and protein stabil-
ity. Ubiquitination of small GTPases controls their be-
havior in cells, including migratory ability and cell cycle
progression. We established recently that FBXL19 tar-
gets RhoA and Rac1 for ubiquitination and degradation,
thus regulating cell growth, stress fiber formation, and
cell migration [17,18]. F-box proteins have been shown
to target multiple-substrates. For example, FBXW7 ubi-
quitinates multiple proteins involved in different signal
pathways, such as Notch, cyclin, c-Myc and c-Jun, for
ubiquination and degradation [39-41]. Here we uncover
that Rac3 is a new substrate for FBXL19 and it interacts
with C-terminus of FBXL19. This is the first study to in-
vestigate Rac3 ubiquitination and degradation. Over-
expression of FBXL19 reduced Rac3 for disposal. In
addition, we identified that FBXL19 induced Rac3 ubi-
quitination at lysine166. This acceptor site is similar to
Rac1 ubiquitin acceptor site from FBXL19, which is dis-
tant from GTP binding site and resides within a C-
terminal α-helix distinct from the polybasic tail [42]. It
has been shown that other ubiquitin E3 ligases such as
IAP and HACE1 also target Rac1 for ubiquitination and
degradation. Since Rac3 shares a high homology with
Rac1, the future study will focus on the role of IAP or
HACE1 in regulation of Rac3 stability.
E-cadherin down-regulation is a fundamental bio-
logical process where epithelial cells lose their polarity
and adopt morphology appropriate for migration [25].
Several studies have shown that E-cadherin down-
regulation is important in cancer progression and is
associated with poor outcome in several tumor sites, in-
cluding non-small cell lung cancer, invasive ductal breast
carcinoma, and gastric adenocarcinoma [43,44]. In tu-
mors of the esophagus and gastroesophageal junction,
disturbances in E-cadherin expression have been corre-
lated with increasing invasive capacity, dedifferentiation,
and lymph node metastases [45]. E-cadherin down-
regulation occurs by canonical TGFβ1 signaling, which
alters the function of the E-cadherin transcriptionalrepressor Snail directly. Rac1 has been known to regu-
late TGFβ1-mediated signaling; however, the role of
Rac3 in TGFβ1-induced E-cadherin has not been stud-
ied. Rac3 is abundantly present in developing and adult
brains, and mildly expressed in the heart, placenta and
pancreas. Hajdo-Milasinovic, A. et al. demonstrated that
Rac3 inhibited adhesion of neuronal cells [46], indicating
Rac3 may regulate E-cadherin expression. In this study,
we show that Rac3 is strongly expressed in esophageal
carcinoma cells and it regulates Snail expression. Inter-
estingly, inhibition of Rac3 by overexpressed inactive
form of Rac3 (Rac3N17), Rac3 shRNA, or FBXL19 sig-
nificantly attenuates TGFβ1-induced E-cadherin down-
regulation (Figure 8). This study discovered that Rac3
plays an important role in the progress of esophageal
cancer cells and the FBXL19 may function as a tumor
suppressor through its ability to reduce Rac3 levels and
inhibits TGFβ1 pathway. Future studies will be con-
ducted to investigate the expression of Rac3 and FBXL19
in esophageal cancer tissues and adjacent normal tissues.
Conclusions
In summary, the current study unveils Rac3 as a new
molecular target of FBXL19. FBXL19 targets Rac3 for
ubiquitination in lysine 166 and induces its proteasomal
degradation. Inhibition of Rac3 by FBXL19 modulates E-
cadherin expression in esophageal cancer cells. This is
the first evidence to support that Rac3 plays a critical
role in the tumorgenesis of esophageal cancer and that
FBXL19 exhibits an anti-tumor property by down-
regulation of small GTPase.
Material and methods
Cells and reagents
Esophageal adenocarcinoma (OE19 and OE33) cancer
cells [Sigma-Aldrich (St. Louis, MO, USA)] were cul-
tured with RPMI 1640 medium containing 2 mM
glutamine and 10% FBS. HEK293 cells [Invitrogen
(Carlsbad, CA, USA)] were cultured with DMEM
medium containing 10% FBS. Murine lung epithelia
(MLE12) cells [American Type Culture Collection
(ATCC), Manassas, VA, USA] were cultured with HITES
medium containing 10% FBS. All the cells were cultured
at 37°C in 5% CO2. V5 antibody, E-cadherine antibody,
mammalian expressional plasmid pcDNA3.1D/His V5
TOPO, Escherichia coli Top 10 competent cells, and re-
combinant TGFβ1 were from Invitrogen (Carlsbad, CA,
USA). HA tag (29 F4), Flag tag (9A3), and ubiquitin
(P4D1) antibodies were from Cell Signaling Technology
(Danvers, MA, USA). Rac3 antibody was from Protein-
tech Group (Chicago, IL, USA). FBXL19 antibody was
from Abgent (San Diego, CA, USA). Leupeptin, ammo-
nium chloride (NH4Cl), β-actin antibody, individual
FBXL19 shRNAs, and scrambled shRNA were from
Figure 8 FBXL19 regulates TGFβ1-induced E-cadherin down-regulation via targeting Rac3 for its degradation - FBXL19 regulates Rac3
degradation in the proteasome system. TGFβ1 induces E-cadherin down-regulation. Over-expression of FBXL19 reduces Rac3 level, thereby inhi-
biting TGFβ1-induced E-cadherin down-regulation.
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cystin from Calbiochem (La Jolla, CA, USA). Immuno-
bilized protein A/G beads were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Superfect trans-
fection reagent was from QIAGEN (Valencia, CA, USA).
All materials in highest grades uses in the experiments
are commercially available.
Construction of FBXL19 and Rac3 plasmids
The FBXL19 cDNA was inserted into a pcDNA3.1D/V5-
His vector (Invitrogen, CA, USA). Site directed muta-
genesis was performed to generate Rac3 lysine or serine
mutant according to the manufacturer’s instructions
(Agilent Technologies, Santa Clara, CA, USA).
Immunoblotting and immunoprecipitation
Cells were washed with cold PBS and collected in cell
lysis buffer containing 20 mM Tris HCl (pH 7.4),
150 mM NaCl, 2 mM EGTA, 5 mM β glycerophosphate,
1 mM MgCl2, 1% Trison X100, 1 mM sodium orthova-
nadate, 10 μg/ml protease inhibitors, 1 μg/ml leupeptin,
and 1 μg/ml pepstatin. An equal amount of cell lysates
(20 μg) was subjected to SDS-PAGE, electrotransferred
to membranes and immunoblotted as described previ-
ously [17,18]. For immunoprecipitation, equal amounts
of cell lysates (1 mg) were incubated with specific pri-
mary antibodies overnight at 4°C, followed by the
addition of 40 μl of protein A/G agarose and incubationfor additional 2 h at 4°C. The immunoprecipitated com-
plex was washed 3 times with 1% Triton X100 in ice
cold phosphate-buffered saline and analyzed by im-
munoblotting with indicated antibodies.
Immunostaining
OE19 cells were plated on 35 mm glass-bottom culture
dishes. After treatment, cells were fixed in 3.7% formal-
dehyde for 20 min, followed by permeabilization with
0.1% Triton X100 for 2 min. Cells were incubated with
1:200 dilution of E-cadherin, followed by a 1:200 dilution
of fluorescence-conjugated secondary antibody sequen-
tially for immunostaining. Immunofluorescent cell im-
aging was performed on a Nikon confocal microscope.
Plasmid transfection
HEK293 cells and OE19 cells were subcultured on 6-
well plates or 35 mm plates for 24 h. Superfect transfec-
tion reagent was used for HEK293 cells and lipofecta-
mine transfection reagent was used for OE19 cells. The
transfection reagent was added to the mixture of 3 μg of
plasmid and 200 μl of reduced serum medium, mixed,
and incubated for 10 minutes to allow transfection re-
agent/DNA complexes to form. And then the mixture
was added directly to the cells. The transfected cells
were cultured for 48 h. shRNA plasmids were also deliv-
ered into cells with the same protocol and the cells were
cultured for 72 h.
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FBXL19-V5 transfected HEK293 and OE19 cells were
cultured in 100-mm dishes and Rac3 activation was eval-
uated using a PBD-GTPγ-Rac3 pull down assay. Briefly,
cell lysates (0.5-1 mg/ml) were loaded with 10 μg of
PAK-1 p21-binding domain fusion-protein conjugated to
agarose for 1 h to bind Rac3-GTP, centrifuged, and
washed three times with lysis buffer. The proteins were
separated by SDS-PAGE, transferred to nitrocellulose
membranes, and probed with a Rac3 antibody. Total cell
lysates were also probed separately with anti-Rac3 and
anti-β-actin antibodies to confirm equal loading.
TGFβ1 treatment
Esophageal cancer cells were cultured in 6-well plates or
35 mm dishes in 10% FBS medium. After 48 h of transfec-
tion, the medium was replaced with 1 ml of serum-free
(blank) medium. TGFβ1 was added into the medium with
the concentration range of 0, 1.25, 2.5, 5.0 10 ng/ml. After
4 days of incubation at 37°C, the cells were collected and
analyzed by immunoblotting with E-cadherin antibodies.
Statistics
All results were subjected to statistical analysis using two-
way analysis of variance, and, wherever appropriate, ana-
lyzed by Student-Newman-Keuls test. Data are expressed
as mean ± SD of triplicate samples from at least three in-
dependent experiments and values that were p < 0.01 were
considered statistically significant.
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